{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Cell+Esophagus+Cancer&page=2",
    "query": {
      "condition": "Squamous Cell Esophagus Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Cell+Esophagus+Cancer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T10:38:18.380Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00601692",
      "title": "Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2003-04",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2013-03-22",
      "last_synced_at": "2026-07-24T10:38:18.380Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00601692"
    },
    {
      "nct_id": "NCT05432193",
      "title": "FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Melanoma (Skin)",
        "Soft Tissue Sarcoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "[Ga-68]-PNT6555",
          "type": "DRUG"
        },
        {
          "name": "[Lu-177]-PNT6555",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2022-07-13",
      "completion_date": "2024-10-02",
      "has_results": false,
      "last_update_posted_date": "2025-06-25",
      "last_synced_at": "2026-07-24T10:38:18.380Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05432193"
    },
    {
      "nct_id": "NCT01868139",
      "title": "Spray Cryotherapy for Esophageal Cancer (ICE-CANCER)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "Liquid nitrogen spray cryotherapy with the truFreeze device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2013-06",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2022-03-07",
      "last_synced_at": "2026-07-24T10:38:18.380Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01868139"
    },
    {
      "nct_id": "NCT04424641",
      "title": "A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Solid Tumor(s)",
        "Prostate Cancer",
        "Esophageal Cancer",
        "Triple Negative Breast Cancer (TNBC)",
        "Squamous Cell Carcinoma of Head and Neck (SCCHN)",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Bladder Cancer",
        "Uterine Cancer"
      ],
      "interventions": [
        {
          "name": "GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2020-07-15",
      "completion_date": "2021-10-29",
      "has_results": true,
      "last_update_posted_date": "2023-07-25",
      "last_synced_at": "2026-07-24T10:38:18.380Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04424641"
    },
    {
      "nct_id": "NCT04000529",
      "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Carcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Esophageal SCC",
        "Gastrointestinal Stromal Tumors",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "TNO155",
          "type": "DRUG"
        },
        {
          "name": "Spartalizumab",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2019-07-30",
      "completion_date": "2024-01-15",
      "has_results": false,
      "last_update_posted_date": "2025-09-30",
      "last_synced_at": "2026-07-24T10:38:18.380Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04000529"
    },
    {
      "nct_id": "NCT00004257",
      "title": "Oxaliplatin and Fluorouracil Plus Radiation Therapy in Treating Patients With Primary Esophageal or Stomach Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Albany Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-01",
      "completion_date": "2004-01",
      "has_results": false,
      "last_update_posted_date": "2013-03-26",
      "last_synced_at": "2026-07-24T10:38:18.380Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004257"
    },
    {
      "nct_id": "NCT05591053",
      "title": "Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Esophagus Cancer",
        "Esophageal Cancer",
        "Esophageal Neoplasms",
        "Esophageal Diseases",
        "Esophageal Adenocarcinoma",
        "Esophageal Squamous Cell Carcinoma",
        "Esophagus SCC",
        "Esophagus Tumor",
        "Esophagus Adenocarcinoma",
        "Esophagus Neoplasm"
      ],
      "interventions": [
        {
          "name": "ActivSight",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Activ Surgical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2023-04-01",
      "completion_date": "2025-01",
      "has_results": false,
      "last_update_posted_date": "2024-02-21",
      "last_synced_at": "2026-07-24T10:38:18.380Z",
      "location_count": 2,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05591053"
    },
    {
      "nct_id": "NCT00258297",
      "title": "Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "gefitinib",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "enzyme inhibitor therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "neoadjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "protein tyrosine kinase inhibitor therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2004-04",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2013-10-16",
      "last_synced_at": "2026-07-24T10:38:18.380Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00258297"
    },
    {
      "nct_id": "NCT01807546",
      "title": "Oral Rigosertib for Squamous Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Anal Squamous Cell Carcinoma",
        "Lung Squamous Cell Carcinoma",
        "Cervical Squamous Cell Carcinoma",
        "Esophageal Squamous Cell Carcinoma",
        "Skin Squamous Cell Carcinoma",
        "Penile Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "rigosertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Traws Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2013-03",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2017-06-26",
      "last_synced_at": "2026-07-24T10:38:18.380Z",
      "location_count": 13,
      "location_summary": "Sacramento, California • Stanford, California • Aurora, Colorado + 10 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01807546"
    },
    {
      "nct_id": "NCT04913337",
      "title": "Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mesothelioma",
        "Glioblastoma",
        "Renal Cell Carcinoma",
        "Non Small Cell Lung Cancer",
        "Melanoma",
        "Pancreatic Ductal Adenocarcinoma",
        "Gastric Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Cholangiocarcinoma",
        "Breast Cancer",
        "Ovarian Cancer",
        "Cervical Cancer",
        "Endocervical Cancer",
        "Colorectal Cancer",
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "NGM707",
          "type": "DRUG"
        },
        {
          "name": "NGM707 plus pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NGM Biopharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 179,
      "start_date": "2021-06-09",
      "completion_date": "2025-07",
      "has_results": false,
      "last_update_posted_date": "2024-10-02",
      "last_synced_at": "2026-07-24T10:38:18.380Z",
      "location_count": 20,
      "location_summary": "Los Angeles, California • Newport Beach, California • Santa Monica, California + 15 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04913337"
    }
  ]
}